Development and validation of a prognostic immunoinflammatory index for patients with gastric cancer

Table 2 Association between prognostic immunoinflammatory index score and clinical characteristics, n (%)

Variable	PII score		P value
	Group 1, n = 130	Group 2, n = 74
Age (years), mean (SD)	58.03 (10.52)	59.18 (10.17)	0.398
Sex			0.301
Male	95 (73.1)	49 (66.2)
Female	35 (26.9)	25 (33.8)
Body mass index (kg/m2), mean (SD)	23.38 (3.13)	22.19 (2.73)	0.004
Radical resection			0.075
Yes	127 (97.7)	68 (91.9)
No	3 (2.3)	6 (8.1)
Primary tumor site			0.016
Upper 1/3	4 (3.1)	4 (5.4)
Middle 1/3	17 (13.1)	11 (14.9)
Low 1/3	99 (76.1)	43 (58.1)
Whole	10 (7.7)	16 (21.6)
Borrmann type			0.275
Ⅰ	16 (12.3)	6 (8.1)
Ⅱ	43 (33.1)	20 (27.0)
Ⅲ	67 (51.5)	42 (56.8)
Ⅳ	4 (3.1)	6 (8.1)
Lymph node positivity
Yes	67 (47.7)	37 (50.0)
No	68 (52.3)	37 (50.0)
Tumor size			0.031
< 20 mm	14 (10.8)	4 (5.4)
20–50 mm	63 (48.5)	26 (35.1)
> 50 mm	53 (40.7)	44 (59.5)
Differentiation			0.100
Poor	43 (33.2)	29 (39.2)
Moderate	70 (53.8)	36 (48.6)
Well	15 (11.5)	4 (5.4)
Unknown	2 (1.5)	5 (6.8)
Lauren type			0.125
Intestinal	67 (51.5)	38 (51.4)
Diffuse	23 (17.7)	12 (16.2)
Mixed	39 (30.0)	19 (25.6)
Unknown	1 (0.8)	5 (6.8)
TNM stage			0.155
Ⅰ	52 (40.0)	29 (39.2)
Ⅱ	34 (26.2)	19 (25.7)
Ⅲ	42 (32.3)	20 (27.0)
Ⅳ	2 (1.5)	6 (8.1)
Carcinoembryonic antigen			0.729
< 1.97 ng/mL	67 (51.5)	40 (54.1)
≥1.97 ng/mL	63 (48.5)	34 (45.9)
CA199			0.032
< 10.19 U/L	73 (56.2)	30 (40.5)
≥ 10.19 U/L	57 (43.8)	44 (59.5)
CA724			0.056
< 2.17 U/L	61 (46.9)	45 (60.8)
≥ 2.17 U/L	69 (53.1)	29 (39.2)
CA125II			0.244
< 10.21 U/L	61 (46.9)	41 (55.4)
≥ 10.21 U/L	69 (53.1)	33 (44.6)
NLR, mean (SD)	1.69 (0.67)	4.24 (4.54)	< 0.001
PLR, mean (SD)	107.02 (31.74)	224.36 (79.72)	< 0.001
SII, mean (SD)	392.19 (180.21)	1196.46 (1134.42)	< 0.001
SIRI, mean (SD)	0.88 (0.48)	2.37 (3.27)	< 0.001
CD3(+) (%), mean (SD)	67.21 (9.87)	72.14 (7.30)	< 0.001
CD3(+)CD4(+) (%), mean (SD)	40.46 (8.14)	41.34 (8.38)	0.445
CD3(+)CD8(+) (%), mean (SD)	22.36 (7.60)	25.47 (8.40)	0.005
CD4(+)/CD8(+), mean (SD)	2.07 (0.94)	1.84 (0.87)	0.069
CD3(+)CD4(+)CD8(+) (%), mean (SD)	0.53 (0.73)	0.76 (2.20)	0.657
CD19(+) (%), mean (SD)	12.58 (4.89)	10.10 (4.09)	< 0.001
CD3(-)CD16(+)CD56(+) (%), mean (SD)	16.99 (9.71)	14.94 (6.92)	0.282
CD3(+)CD16(+)CD56(+) (%), mean (SD)	3.17 (5.48)	3.41 (3.67)	0.202

CA125II: Carbohydrate antigen 125II; CA199: Carbohydrate antigen 199; CA724: Carbohydrate antigen 724; NLR: Neutrophil-to-lymphocyte ratio; PII: Prognostic immunoinflammatory index; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune inflammatory index; SIRI: Systemic inflammation response index; TNM: Tumor-node-metastasis.